admin

ViacomCBS (NASDAQ:VIAC) has been a costly disappointment for some investors in 2021. Enthusiasm over the company’s newly-announced streaming plans paired with Reddit-fueled retail investors drove VIAC stock past $100 three weeks into March. That was a 174% gain in under four months. Source: Jer123 / Shutterstock.com A catastrophic crash then saw shares lose half their
0 Comments
A bit of positive news included in Carnival’s (NYSE:CCL) second-quarter results lifted CCL  stock in late September. But even as the world appears on track to get “back to normal,” you may not want to buy Carnival’s shares at its present levels. There’s a good chance that the cruise line operator’s results will fully bounce
0 Comments
Hey everybody, Dave Bartosiak with Trending Stocks for Zacks.com. Roku is nearing a distribution deal with AT&T for HBO Max. Not to be confused with Boeing’s Death Trap that is the 737 MAX nor HBO GO nor HBO Now. It’s HBO’s standalone streaming service that will set you back $15 a month. Rumors about a
0 Comments
A year ago, electric vehicles (EVs) were a promising sector for investors. But in 2021, that all changed. Sponsors of special purpose acquisition companies (SPACs) flooded the market with new EV stock investments. Some of these, like Lucid Motors (NASDAQ:LCID), have worked out pretty well. Most, however, have been terrible for investors. Unfortunately, Lordstown Motors
0 Comments
Here’s a rare opportunity for you. A “next-generation Medicare Advantage insurer,” Clover Health (NASDAQ:CLOV) operates in a high-potential market, providing health care access to seniors and other patient demographics. Yet, CLOV stock is trading at a surprisingly low price. Source: Shutterstock Currently, this stock has landed gently at a strong support level. So, it might be
0 Comments
After rising over $100 briefly this year, Cassava Sciences (NASDAQ:SAVA) stock is struggling to rebound. A long document written by the lawyer of a short-seller sent SAVA stock lower. The document challenged the accuracy of some of Cassava’s clinical results Source: Atthapon Raksthaput / Shutterstock.com Cassava has two major clinical studies underway. The top-line data
0 Comments
With the seemingly worsening crisis of property developer China Evergrande (OTCMKTS:EGRNF), it may be time for investors to at least consider reducing exposure to companies tied to the world’s second-largest economy. Late last week, the Wall Street Journal reported that Evergrande failed to make a scheduled interest payment last Thursday, sparking concerns about a mass
0 Comments